Alvotech has enrolled the first patient, among expected 400, to test its Humira biosimilar candidate in Alvopad PS, in a Phase III clinical study (ALVOPAD PS), for adult patients with moderate to severe chronic plaque psoriasis.
The AVT02 formulation contains a high concentration (100 mg/ml) of adalimumab, which is expected to be more convenient for patients, for example, based on the reduced injection volume. With AVT02, Alvotech said it is well positioned to differentiate from biosimilars competitors.
Robert Wessman, founder of Alvotech, and chairman of the board, said that the company’s first biosimilar product enrolling its first patient is a major step forward in the development of Alvotech’s biosimilars portfolio. “Alvotech is well positioned to take on opportunities in the global biosimilars market,” he said.
Dr. Fausto Berti, Alvotech SVP and head of clinical and late stage development at Alvotech, said the company homes to to reach future patients with a more convenient, cost-effective version of adalimumab,
with AVT02 containing biosimilar adalimumab at high concentration (100 mg/ml).